Cargando…
Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
Rapid remission of MDS/AML may be induced with Decitabine; however, significant megakaryocyte expansion and subsequent thrombocytosis may occur. Decitabine‐mediated reversion of the MDS to benign ET via hypomethylation of JAK/STAT pathway repressors is one potential mechanism to explain this observe...
Autores principales: | Horton, Joshua D., Arbini, Arnaldo A., Perle, Mary Ann, Raphael, Bruce G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706408/ https://www.ncbi.nlm.nih.gov/pubmed/26783435 http://dx.doi.org/10.1002/ccr3.431 |
Ejemplares similares
-
Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022) -
Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
por: Li, Hongjiao, et al.
Publicado: (2023) -
An Ulceronecrotic Foot Lesion in a Patient with Essential Thrombocythemia: Successful Treatment with Hydroxyurea
por: Kato, Tokue, et al.
Publicado: (2012) -
Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019) -
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
por: Hilberink, Jacobien R., et al.
Publicado: (2023)